8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2010

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
(State or other	(Commission	(IRS employer
jurisdiction of	file number)	identification no.)
incorporation)

One Boston Scientific Place, Natick, Massachusetts	01760-1537
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code:   (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01.  OTHER EVENTS.

As a follow-up to the actions described in Boston Scientific’s press releases of March 15 and April 15, 2010, the Company has received U.S. Food and Drug Administration clearance for manufacturing changes to its LIVIAN™ and RENEWAL® cardiac resynchronization therapy defibrillators (CRT-Ds) and CONFIENT™, PRIZM™ and VITALITY™ implantable cardioverter defibrillators (ICDs) and is immediately resuming U.S. distribution of these products.   The Company has now resumed U.S. distribution of all its CRT-D and ICD devices.

ITEM 9.01.                      FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit No Description

Exhibit 99.1:  Letter to Physicians.

Exhibit 99.2:  Letter to Patients.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BOSTON SCIENTIFIC CORPORATION
Date:   May 20, 2010	By:	/s/ Timothy A. Pratt
		Timothy A. Pratt
		Executive Vice President, Chief Administrative Officer, General Counsel and Secretary

- 3 -

INDEX TO EXHIBITS

Exhibit No Description

Exhibit 99.1:  Letter to Physicians.

Exhibit 99.2:  Letter to Patients.

- 4 -

EX-99.1

Exhibit 99.1

4100 Hamline Avenue North

St. Paul, MN 55112-5798

www.bostonscientific.com

May 2010

Subject: U.S. distribution of all Boston Scientific CRT-D and ICD devices has resumed

Dear Doctor:

We are writing to inform you that we have received U.S. Food and Drug Administration clearance for manufacturing changes to our LIVIAN™ and RENEWAL® cardiac resynchronization therapy defibrillators (CRT-Ds) and CONFIENT™, PRIZM™ and VITALITY™ implantable cardioverter defibrillators (ICDs), and we have resumed U.S. distribution of these products.  We have now resumed U.S. distribution of all our CRT-Ds and ICDs, and you may implant all these devices.  Your local sales representative will work with your hospital to replenish inventory.

Throughout this process there has been no indication of any risk to patient safety.  We do not recommend any modifications to normal follow-up procedure for patients previously implanted with Boston Scientific CRT-Ds or ICDs.

We are pleased we are again able to provide you and your patients the benefits of our defibrillation products.  We would like to thank you for your patience and support as we worked through this situation.

If you have questions, please contact your local Boston Scientific sales representative or U.S. Technical Services at 1.800.CARDIAC (227.3422).

Sincerely,

Hank Kucheman Group President; Cardiology, Rhythm & Vascular Boston Scientific Corporation Kenneth Stein, M.D. Chief Medical Officer Boston Scientific CRM

EX-99.2

Exhibit 99.2

4100 Hamline Avenue North

St. Paul, MN 55112-5798

www.bostonscientific.com

May 2010

Dear Patient:

We want you to know that we have resumed distribution of all of our cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) to hospitals in the United States.  Throughout this process there has been no indication of any risk to patient safety, so there is nothing you or your heart doctor need to do differently for your implanted device.

We encourage you to contact your heart doctor or Boston Scientific Patient Services if you have questions.  You can reach our Patient Services team by calling 1.866.484.3268 and pressing “2” when prompted.

Sincerely,

Hank Kucheman Group President; Cardiology, Rhythm & Vascular Boston Scientific Corporation Kenneth Stein, M.D. Chief Medical Officer Boston Scientific CRM